Clinical trials: FAP
Pancreatic Ductal Adenocarcinoma, Pancreatic Cyst
The Pancreas Interception Center (PIC) for Early Detection, Prevention, and Novel Therapeutics
The long-term goal of our PIC is to develop effective strategies that can be applied clinically at the point-of-care to prevent, intercept, or detect PDAC at an early stage, thereby reducing PDAC burden and saving lives.
- Conditions
- Pancreatic Ductal Adenocarcinoma, Pancreatic Cyst, Chronic Pancreatitis, Fatty Pancreas
- Trial name
- NCT05692596
- Testing
- Data collection
- Where
- United States
- Volunteers
- 317 people, healthy volunteers welcome
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
PSMA-related Disease, Prostate Cancer
Prostate Specific Membrane Antigen PET/CT Imaging in PSMA-Related Disease Patients
To evaluate the potential usefulness of 68Ga/18F-PSMA/PSFA positron emission tomography/computed tomography (PET/CT) for the diagnosis of primary and metastatic lesions in various PSMA-related disease patients (prostate cancer…
- Conditions
- PSMA-related Disease, Prostate Cancer, Positron Emission Tomography, Metastasis
- Trial name
- NCT06690970
- Testing
- 68Ga/18F-PSMA/PSFA
- Where
- 3 sites in China
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Tianjin Medical University
SSTR2, FAP
68Ga-FAPI-LM3 PET/CT Imaging in Patients With FAP/SSTR2 Positive Disease and Compared With 18F-FDG
As a new dual receptor (SSTR2 and FAP) targeting PET radiotracer, 68Ga-FAPI-LM3 is promising as an excellent imaging agent applicable to SSTR2 positive diseases.
- Conditions
- SSTR2, FAP, Positron-Emission Tomography
- Trial name
- NCT05873777
- Testing
- 18F-FDG PET/CT, 68Ga-FAPI-LM3 PET/CT
- Where
- China
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- The First Affiliated Hospital of Xiamen University
PSMA, FAP
68Ga-PSFA PET Imaging in Patients With PSMA/FAP Positive Disease
As a new dual receptor (PSMA and FAP) targeting PET radiotracer, 68Ga-PSFA is promising as an excellent imaging agent applicable to PSMA/FAP positive diseases.
- Conditions
- PSMA, FAP, Positron-Emission Tomography
- Trial name
- NCT06387381
- Testing
- 68Ga-PSFA
- Where
- China
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- First Affiliated Hospital of Chongqing Medical University
PASC Post Acute Sequelae of COVID 19, Long COVID
From Inflammation to Remodelling Towards Personalized Diagnosis in Post-acute Sequelae of COVID-19
Rationale: The diagnosis and pathogenesis of long COVID remains unknown. We have previously shown that [68Ga]FAPI Positron Emission Tomography-Computed Tomography (PET/CT) imaging shows potential for diagnosis and molecular…
- Conditions
- PASC Post Acute Sequelae of COVID 19, Long COVID, Long Covid-19, PASC
- Trial name
- LIBERATE (NCT06911476)
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- University Medical Center Groningen
Lynch Syndrome, Li Fraumeni Syndrome
Video Capsule Examination in Patients With Lynch Syndrome
Surveillance for colorectal cancer (CRC) in patients predisposed to develop CRC during their lifetime has been impacted by access to colonoscopy suites and endoscopy specialists in the past couple of years.
- Conditions
- Lynch Syndrome, Li Fraumeni Syndrome, PTEN Hamartoma Syndrome, FAP
- Trial name
- PILLCAM (NCT06712095)
- Testing
- Video capsule investigation
- Where
- United Kingdom
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Royal Marsden NHS Foundation Trust
Cancer, FAP
18F-FAPI-04 PET/CT and PET/MR in Patients With Various Types of Malignant Tumors
To evaluate the potential usefulness of 18F-FAPI-04 positron emission tomography/computed tomography (PET/CT) and positron emission tomography/magnetic resonance imaging （PET/MR）for the diagnosis of primary and metastatic…
- Trial name
- NCT06557590
- Testing
- 18F-FAPI-04
- Where
- China
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Hunan Cancer Hospital
Familial Amyloid Polyneuropathy (FAP)
Study of SOM0226 in Familial Amyloid Polyneuropathy
Clinical proof of concept study to evaluate SOM0226 efficacy in TTR Amyloidosis.
- Trial name
- NCT02191826
- Testing
- SOM0226
- Where
- Spain
- Volunteers
- 17 people, healthy volunteers welcome
- Sponsor
- SOM Innovation Biotech SA